Contribution: Industrial Research Assistance Program – Contributions to Firms
Kisoji Biotechnologie Inc.
$500,000.00
Accelerating Antibody Modeling with AI: Speeding up In-Silico Drug Discovery
FY 2024-25 · 2024-10-17
Summary
The firm will use machine learning to predict the 3D structure of antibodies more accurately and rapidly than existing technologies. A tool will be developed to provide antibody structures. The enhanced AI-enabled platform will be used to search and identify therapeutic antibodies.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Montreal|Montréal, Quebec, Canada
Recipient Type
For-profit organization
Business Number
858257454
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2024-10-17 | 2024-25 | $500,000.00 |
| 2 | 2024-10-17 | 2024-25 | $500,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 74 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 74 jours.
Agreement End Date
2026-03-31
Agreement Number
1024128
Agreement Start Date
2024-10-17
Agreement Title
Accelerating Antibody Modeling with AI: Speeding up In-Silico Drug Discovery
Agreement Title (French)
Accélérer la modélisation des anticorps grâce à l’IA : accélérer la découverte de médicaments in silico
Agreement Type
Contribution
Agreement Value
$500,000.00
Amendment Date
2025-12-03
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The firm will use machine learning to predict the 3D structure of antibodies more accurately and rapidly than existing technologies. A tool will be developed to provide antibody structures. The enhanced AI-enabled platform will be used to search and identify therapeutic antibodies.
Description (French)
L’entreprise utilisera l’apprentissage automatique pour prédire la structure 3D des anticorps avec plus de précision et de rapidité que les technologies existantes. Un outil sera mis au point pour fournir des structures d’anticorps. La plateforme améliorée basée sur l’IA sera utilisée pour rechercher et identifier des anticorps thérapeutiques.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding (French)
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number
24077
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
858257454
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
Kisoji Biotechnologie Inc.
Recipient Postal Code
H2X 2J1
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2024-2025-Q3-1024128
